Navitor Pharmaceuticals Inc. is betting selective inhibitors of mammalian target of rapamycin complex 1 (mTORC1) will lead to reduced toxicity compared to drugs targeting both mTORC1 and mTORC2, and expects it will be able to take its hypothesis into the clinic with a new $23.5 million series A round.

Polaris Partners; Atlas Venture; Johnson & Johnson Development Corp. (JJDC); SR One; and The Longevity Fund participated in last week's tranched round. JJDC is